Global Leading Market Research Publisher QYResearch announces the release of its latest report “Long-acting Inhaled Medicines (LAIM) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Long-acting Inhaled Medicines (LAIM) market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: Respiratory patients (COPD, asthma) require daily maintenance therapy – but frequent dosing reduces adherence and clinical outcomes. Long-acting inhaled medicines (LAIM) solve this with once or twice daily administration through molecular engineering (LABA, LAMA), controlled-release formulations, and advanced particle design. Key drivers include adherence improvement, fixed-dose combinations, and generic LAMA/LABA entry.
The global market for Long-acting Inhaled Medicines (LAIM) was estimated to be worth US$ 2,812 million in 2025 and is projected to reach US$ 3,706 million, growing at a CAGR of 4.1% from 2026 to 2032. In 2024, the average price was approximately US$ 12.68 per unit, with total sales reaching around 213 million units.
Long-acting inhaled medicines (LAIM) achieve prolonged therapeutic effects through molecular engineering and advanced pharmaceutical technologies, reducing dosing frequency and improving patient adherence. Typical LAIM include long-acting beta-agonists (LABA) and long-acting muscarinic antagonists (LAMA), often requiring only once or twice daily administration. Additionally, pharmaceutical strategies such as controlled-release formulations, mucoadhesive systems, and large porous particle designs are employed to extend the pharmacological effect post-inhalation, providing sustained treatment benefits.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098557/long-acting-inhaled-medicines–laim
Market Segmentation & Key Players
The Long-acting Inhaled Medicines (LAIM) market is segmented as below:
Leading Suppliers: Boehringer Ingelheim, Teva Pharmaceutical, Novartis, The Menarini Group, Covis Pharma, Zentiva, Alfasigma, Gebro-Pharma, Kohl Medical, Cipla, GSK, Viatris, LEK-AM, AstraZeneca, Chiesi Farmaceutici, Orion Corporation, Polpharma, Adamed Group, STADA Arzneimittel, Zhejiang Xianjun Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, Nanchang Helioeast Technology.
Segment by Type: Long-acting Muscarinic Antagonists (LAMAs) | Long-acting Beta-Agonists (LABAs)
Segment by Application: Asthma | COPD | Others
Exclusive Industry Insights
Advanced inhalation formulation technologies: LAIM employ multiple strategies for prolonged action:
- Molecular engineering: Extended half-life (e.g., indacaterol 24h, tiotropium 24h+).
- Controlled-release particles: Large porous particles (>5μm) for sustained deposition.
- Mucoadhesive systems: Prolonged residence time in airways.
Technical differentiation – LAIM classes:
| Class | Mechanism | Duration | Formulation Approach |
|---|---|---|---|
| LAMA | M3 receptor antagonist | 24h+ | High receptor affinity, slow dissociation |
| LABA | Beta-2 agonist | 12–24h | Lipid conjugation, sustained release |
Recent 6-month data (Oct 2025 – Mar 2026):
- COPD largest application (68% revenue), asthma 28%.
- LAMA + LABA fixed-dose combinations fastest-growing (CAGR 5.5%), now 48% of LAIM prescriptions.
- Generic LAIM share reached 35% in Europe, 25% in US.
User case – European health system (UK, 1.5 million respiratory patients): Shifting from twice-daily to once-daily LAIM formulations improved adherence from 58% to 71% over 12 months. Exacerbation rates decreased 14%, saving US$ 38M annually in hospitalization costs.
Adherence impact of once-daily vs. twice-daily:
| Dosing Frequency | Adherence Rate (12 months) |
|---|---|
| Once daily | 71% |
| Twice daily | 58% |
| Three+ times daily | 45% |
Application insights: COPD (68%) – LAMA first-line, LABA/LAMA combinations for moderate-severe. Asthma (28%) – LABA as add-on to ICS (step 3–5). Others (4%) – off-label, pediatric, rare diseases.
Emerging LAIM technologies:
- Dry powder formulations: Carrier-based (lactose) or carrier-free (spray-dried).
- Soft mist inhalers: Respimat platform for slow-moving aerosol.
- Nano-carriers: Liposomes, PLGA particles for sustained release (preclinical).
Regional snapshot: North America leads with 46% revenue share (higher branded prices). Europe holds 28% (strong generic penetration). Asia-Pacific fastest-growing (CAGR 5.2%), driven by COPD diagnosis.
Conclusion
The long-acting inhaled medicines market is mature but growing, driven by once-daily convenience, fixed-dose combinations, and generic entry. Success depends on novel particle engineering, device usability, and combination product development. The projected US$ 3.71 billion market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
